RSU vesting drives insider trades at Day One (NASDAQ: DAWN)
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Day One Biopharmaceuticals’ Chief Commercial Officer Lauren Merendino reported several equity transactions. On February 17, 2026, she sold 5,814 shares of common stock in an open-market sale at a weighted average price of $11.6009 per share, solely to cover tax liabilities from RSU settlements.
On February 15, 2026, multiple Restricted Stock Units converted into common stock at no cost, increasing her direct holdings. Footnotes state each RSU converts into one common share, does not expire, and vests in scheduled quarterly installments contingent on continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 5,814 shares ($67,448)
Net Sell
9 txns
Insider
Merendino Lauren
Role
Chief Commercial Officer
Sold
5,814 shs ($67K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 5,814 | $11.6009 | $67K |
| Exercise | Restricted Stock Unit (RSU) | 3,162 | $0.00 | -- |
| Exercise | Restricted Stock Unit (RSU) | 3,688 | $0.00 | -- |
| Exercise | Restricted Stock Unit (RSU) | 3,687 | $0.00 | -- |
| Exercise | Restricted Stock Units (RSU) | 4,625 | $0.00 | -- |
| Exercise | Common Stock | 3,162 | $0.00 | -- |
| Exercise | Common Stock | 3,688 | $0.00 | -- |
| Exercise | Common Stock | 3,687 | $0.00 | -- |
| Exercise | Common Stock | 4,625 | $0.00 | -- |
Holdings After Transaction:
Common Stock — 60,157 shares (Direct);
Restricted Stock Unit (RSU) — 18,978 shares (Direct);
Restricted Stock Units (RSU) — 69,375 shares (Direct)
Footnotes (1)
- Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs. The price reported in Column 4 is a weighted average price. These shares were sold as part of block trades for multiple security holders of the Issuer at prices ranging from $11.195 to $11.8508, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein with regard to the block trade. The RSUs vested as to 1/4th of the total award on August 15, 2024, and the remaining 3/4 of the award vests in 12 substantially equal quarterly installments thereafter on November 15, February 15, May 15 and August 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. RSUs do not expire; they either vest or are canceled prior to the vesting date. The RSUs vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
FAQ
What insider transactions did DAWN’s Chief Commercial Officer report?
Lauren Merendino reported an open-market sale of 5,814 shares of Day One Biopharmaceuticals common stock at a weighted average price of $11.6009 per share, along with multiple RSU conversions into common stock at no cost following scheduled vesting on February 15, 2026.
What RSU terms apply to DAWN’s Chief Commercial Officer’s awards?
Each Restricted Stock Unit represents a contingent right to receive one share of Day One Biopharmaceuticals common stock for no consideration. Footnotes explain RSUs either vest or are canceled and follow quarterly vesting schedules tied to continued service on specific dates such as February 15 and August 15.
How do the RSUs for DAWN’s Lauren Merendino vest over time?
One RSU grant vested 1/4 of the award on August 15, 2024, with the remaining 3/4 vesting in 12 equal quarterly installments on November 15, February 15, May 15, and August 15. Another grant vests 1/16 in quarterly installments on those same dates.
Did the DAWN insider pay cash to exercise RSUs into common stock?
The RSU conversions into common stock occurred at a reported price of $0.0000 per share. Footnotes clarify each RSU converts into one common share for no consideration, meaning the insider did not pay cash to receive those shares upon vesting and settlement.